Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
ADAM12 Rabbit anti-Human, Polyclonal, Bioss

Rabbit Polyclonal Antibody
Supplier: Bioss BS5847R

Description
ADAM12 is a member of the ADAM (a disintegrin and metalloprotease-like domain) family. Two forms of ADAM12 have been described: ADAM12S and ADAM12L (short and long forms). The short form is a soluble form lacking the transmembrane and cytoplasmic domains. The short form of ADAM12 was reported to provoke myogenesis, and the lack of cytoplasmic domain suggests different regulation pathways (although both forms can be expressed in the same tissue).Specifications
ADAM12 | |
Polyclonal | |
Unconjugated | |
ADAM12 | |
a disintegrin and metallopeptidase domain 12 (meltrin alpha); a disintegrin and metalloprotease domain 12; a disintegrin and metalloproteinase; a disintegrin and metalloproteinase domain 12 (meltrin alpha); ADAM; ADAM 12; ADAM metallopeptidase domain 12; Adam12; ADAM12-OT1; ADAMs; CAR10; Disintegrin and metalloproteinase domain-containing protein 12; MCMP; MCMPMltna; meltrin alpha; Meltrin-alpha; metalloendopeptidases; metalloprotease-disintegrin 12 transmembrane; mKIAA4001; MLTN; Mltna; PRO545; RP11-295J3.5; UNQ346; UNQ346/PRO545 | |
Rabbit | |
Protein A | |
RUO | |
8038 | |
-20°C | |
Liquid |
Flow Cytometry, Immunofluorescence, Immunohistochemistry (Paraffin), Western Blot | |
1 μg/mL | |
PBS with 1% BSA, 50% glycerol and 0.09% sodium azide; pH | |
O43184 | |
ADAM12 | |
KLH conjugated synthetic peptide derived from human ADAM12. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction